The SR-like splicing factor SFRS10 (Htra2-beta1) is well known to influence various alternatively spliced exons without being an essential splicing factor. We have shown earlier that SFRS10 binds SMN1/SMN2 RNA and restores full-length (FL)-SMN2 mRNA levels in vitro. As SMN1 is absent in patients with spinal muscular atrophy (SMA), the level of FL-SMN2 determines the disease severity. Correct splicing of SMN2 can be facilitated by histone deacetylase inhibitors (HDACis) via upregulation of SFRS10. As HDACis are already used in SMA clinical trials, it is crucial to identify the spectrum of alternatively spliced transcripts modulated by SFRS10, because elevated SFRS10 levels may influence or misregulate also other biological processes. To address this issue, we generated a conditional Sfrs10 allele in mice using the Cre/loxP system. The ubiquitous homozygous deletion of Sfrs10, however, resulted in early embryonic lethality around E7.5, indicating an essential role of Sfrs10 during mouse embryogenesis. Deletion of Sfrs10 with recombinant Cre in murine embryonic fibroblasts (MEFs) derived from Sfrs10 fl/fl embryos increased the low levels of SmnD7 3 -4-fold, without affecting FL-Smn levels. The weak influence of Sfrs10 on Smn splicing was further proven by a Hb9-Cre driven motor neuron-specific deletion of Sfrs10 in mice, which developed normally without revealing any SMA phenotype. To assess the role of Sfrs10 on FL-SMN2 splicing, we established MEFs from Smn 2/2 ;SMN2 tg/tg ;Sfrs10 fl/fl embryos. Surprisingly, deletion of Sfrs10 by recombinant Cre showed no impact on SMN2 splicing but increased SMN levels. Our findings highlight the complexity by which alternatively spliced exons are regulated in vivo.
INTRODUCTION
The SR-like splicing factor SFRS10 (splicing factor arginine(R)-serine(S)-rich 10), also denoted as Htra2-beta1, contributes to alternative splicing processes in a concentrationdependent manner and changes in SFRS10 concentration have been shown to affect splice site selection (1, 2) . Misregulation of SFRS10 levels has been associated with several pathologic conditions, including tumorigenesis, stroke, nerve injury, arteriosclerosis and silicosis (3 -7) .
Usually, various different splicing factors facilitate or repress the inclusion or exclusion of alternative exons (8) . SFRS10 binds to a highly degenerated purine-rich sequence motif (GAARGARR) (9) and influences various alternatively spliced exons as demonstrated by in vitro experiments. SFRS10 has been shown to regulate alternative splicing of clathrin, FGF-2R and GluR-B, which are involved in neuronal processes (10, 11) , MYPT1, which is involved in smooth muscle differentiation (12) and HipK3-T, a testis-specific transcript (13, 14) . Furthermore, SFRS10 is involved in the correct * To whom correspondence should be addressed at: Institute of Human Genetics, University of Cologne, Kerpener Street 34, Cologne 50931, Germany. Tel: +49 22147886464; Fax: +49 22147886465; Email: brunhilde.wirth@uk-koeln.de splicing of several transcripts, which, if aberrantly spliced cause different disorders: examples have been shown for Tau in frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) (11, 15, 16) , for CFTR in cystic fibrosis (17) , CD44 in tumorigenesis (6, 18) and for SMN1 and SMN2 in spinal muscular atrophy (SMA) (19, 20) .
SMA is one of the most common autosomal recessively inherited disorders in human and cause of early death in childhood. SMA is caused by homozygous deletions/mutations of SMN1 that leads to progressive functional loss of a-motor neurons in the anterior horns of the spinal cord (21, 22) . The severity of SMA is primarily determined by the copy number of SMN2, an almost identical copy gene localized in the vicinity of SMN1 (23 -26) . Owing to a single translationally silent mutation in exon 7 (c840C.T), SMN2, in contrast to SMN1, produces mainly alternatively spliced transcripts lacking exon 7 (SMN2D7) (27) . This transition in SMN2 exon 7 disrupts an exonic splicing enhancer (ESE) for SF2/ ASF and creates a novel splicing silencer for hnRNP-A1 (28, 29) . SFRS10 binds specifically to another ESE within the central part of exon 7 and promotes correct splicing of SMN2 and also of SMN1 (19) . SFRS10 acts within a network of further splicing factors including, hnRNP-G, SRp30c and TDP-43 and is therefore responsible for 10% full-length (FL) SMN2 transcripts (19, 20, 30, 31) . Upregulation of SFRS10 in cell culture restores the correct SMN2 splicing to almost 80% (19, 20) . However, the final proof that, also in vivo, SFRS10 has indeed a major impact on the alternative splicing of the above-mentioned transcripts needs to be furnished.
As each SMA patient carries at least one SMN2 copy, modulation of the correct splicing of SMN2 is thought to open a potential therapeutic possibility for SMA. Indeed, a large number of histone deacetylase inhibitors (HDACis), such as valproic acid, SAHA, M344 and others, are able to increase the FL-SMN2 transcript in vitro and in vivo (32) (33) (34) (35) (36) (37) . As both, SMN and SFRS10, increase under HDACi treatment, the partially restored FL-SMN2 levels may be facilitated by elevated SFRS10 levels (32, 34) . Owing to elevated SFRS10 levels upon HDACi treatment, the identification of the spectrum of transcripts regulated by SFRS10 is essential.
SFRS10 is widely expressed and highly conserved among species, with 100% identity on protein level with the murine Sfrs10. The Drosophila ortholog of SFRS10, transformer 2 (tra2), is together with transformer (tra) involved in sexual differentiation and spermatogenesis (38) . Deficiency of tra2 in Drosophila causes sex reversion and sterility with no other phenotypic abnormalities (38) . These data strongly support the hypothesis that-at least in Drosophila-tra2 is a non-essential splicing factor.
To better understand the role of SFRS10 in mammals, we generated a conditional Sfrs10 allele in the mouse. In contrast to the phenotype in Drosophila, ubiquitous Sfrs10 deficiency in mice resulted in early embryonic lethality proving a crucial role during early embryonic development. Unexpectedly, Cre-driven Sfrs10 deletion in primary murine embryonic fibroblasts (MEFs) derived either from Sfrs10 fl/fl or Smn 2/2 ; SMN2 tg/tg ; Sfrs10 fl/fl embryos had no significant influence on the correct splicing of neither murine FL-Smn nor human FL-SMN2 pre-mRNA. Accordingly, motor neuron-specific deletion of Sfrs10 in mice had also no developmental or phenotypic consequences. Our data emphasizes that in vivo deletion of a certain splicing factor may not coincide with the expected result based on in vitro overexpression experiments using minigenes.
RESULTS

Conditional gene targeting of Sfrs10 and generation of Sfrs10-deficient mice
To investigate the Sfrs10 function in vivo, we generated a conditional Sfrs10 allele by homologous recombination in ES cells. The murine Sfrs10 gene with a size of 20 kb is located on chromosome 16 and spans 10 exons (7). We constructed a gene replacement vector that introduced one loxP site and a neomycin resistance gene (neo) upstream of exon 4 and one loxP site downstream of exon 4 of the endogenous Sfrs10 gene. Deletion of exon 4 upon Cre-mediated recombination resulted in a frameshift mutation and in a premature stop codon in exon 5 (Fig. 1A) . Sfrs10 flneo/+ ES cells were identified via Southern blot analysis (Fig. 1B-D) and afterwards introduced into blastocysts. Resulting chimeric mice were mated to C57BL6/N Crl mice and germline transmission was confirmed by Southern blot analysis (Fig. 1B) and PCR (data not shown). To generate the conditional Sfrs10 fl allele, the FRT-site-flanked neomycin resistance gene was removed by use of the FLPe-deleter line (39) . Heterozygously floxed Sfrs10 offspring was intercrossed to generate the Sfrs10 fl/fl line ( Fig. 1E and F) . Heterozygous Sfrs10 +/2 mice were generated by breeding Sfrs10 flneo/+ mice with the deleter-Cre line (40) . Mice heterozygous for the Sfrs10 deficiency, genotyped by PCR and Southern blotting ( Fig. 1G and H) , displayed no phenotypic abnormalities. A complete list of all generated lines, probes and primers is given in Tables 1 -3 . Sfrs10 +/2 mice showed normal fertility and normal lifespan, even though reduced Sfrs10 protein levels were detected by western blot analysis in brain, testis and whole body lysate of embryos at E12.5 (Fig. 2) .
Sfrs10 deficiency results in early embryonic lethality
Sfrs10
+/2 mice were intercrossed in order to obtain Sfrs10 2/2 mice. Among more than 200 offspring investigated only Sfrs10 +/2 (68%) and Sfrs10 +/+ (32%), but no viable Sfrs10 2/2 mice were detected (Table 4) , leading to the assumption that the homozygous absence of Sfrs10 results in embryonic lethality. This conclusion was further supported by the finding that also intercrosses of Sfrs10 flneo/+ mice carrying the neomycin cassette did not generate viable Sfrs10 flneo/flneo progeny ( Table 4 ), suggesting that the Neo(R) cassette disrupted the proper function of Sfrs10.
In order to define the time point of embryonic lethality, we prepared embryos resulting from Sfrs10 +/2 intercrosses at different stages of embryonic development, assessed by the presence of a vaginal plug at E0.5. The obtained embryos were dissected and genotyped by PCR (Table 3) . We detected neither at embryonic day E12.5 nor on day E10.5 any Sfrs10 2/2 embryos. As indicated in Table 4 , the ratio of wild-type and heterozygous embryos was roughly 1:2.
Human Molecular
However, we observed a high number of resorbed embryos ( 30%; (Table 4) ]. Genotypes were confirmed by PCR with three different primer combinations using amplified genomic DNA (Table 3) .
Preparations and subsequent genotyping at E9.5 and E8.5 revealed Sfrs10 2/2 embryos, which were easily distinguishable from littermates of the other genotypes (Fig. 3) .
Sfrs10
2/2 embryos were clearly reduced in size when compared with wild-type or Sfrs10 +/2 littermates of the 
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other genotypes and some of them started already being resorbed ( Table 4 ). The only structure we detected, at least in some cases, was the allantois, which in Sfrs10 +/+ or Sfrs10 +/2 littermates was already integrated into the umbilical cord at E9.5. None of the Sfrs10 2/2 embryos showed any vascularization or perfusion when compared with the littermates.
Sfrs10
+/+ and Sfrs10 +/2 embryos displayed slight developmental differences among each other which did, however, not correlate with the genotype (Fig. 3A) . The number of Sfrs10 2/2 embryos detected at E9.5 was slightly lower than expected, most likely they could not be properly genotyped due to the advanced resorption ( Table 4) .
The results indicate that Sfrs10 2/2 embryos die between E7.5 and E8.5 and suggest an essential role of Sfrs10 during early embryogenesis post-implantation.
Expression profile of Sfrs10 at different embryonic stages
In order to further analyze Sfrs10 2/2 embryos, we performed immunohistochemical analysis. We intercrossed Sfrs10 +/2 mice, and females were sacrificed at the respective day of embryonic development. The deciduae were dissected and subsequently prepared for immunohistochemical analyses. Wild-type or Sfrs10 +/2 embryos showed an ubiquitous expression of Sfrs10 in the nuclei of the embryo and the extra embryonic compartments at E6.5 -8.5, whereas Sfrs10 2/2 embryos failed to express Sfrs10 (Fig. 4) . However, embryos did not differ in development and size until E7.5. Sfrs10 2/2 embryos at E7.5 were already reduced in size when compared with control littermates, which correlates with the lethality between E7.5 and E8.
Sfrs10 deficiency in MEFs does not change Smn protein or transcript levels
The early lethal phenotype of Sfrs10 2/2 embryos impeded any functional analysis of the splicing factor with regard to Smn splicing. We therefore intercrossed MEFs with recombinant His-TAT-NLS-Cre (HTNC) (41) . On DNA level, the entire Sfrs10 deletion was determined 48 h after HTNC treatment when compared with cells treated only with DMEM (without FCS) and PBS (mock) (Fig. 5A ). The complete deletion of Sfrs10 was further confirmed by an independent PCR which specifically amplifies only the floxed allele (Supplementary Material, Fig. S1 ). Cells deficient for Sfrs10 showed no morphological changes or proliferative defects (Fig. 5B) . Deletion of Sfrs10 was assessed on transcript level by quantitative real-time PCR (qRT-PCR) for all three time points after HTNC application. Sfrs10 levels were found to be only 2 -4% of the mock treated cells (Fig. 5C ). Depletion of Sfrs10 was confirmed by western blot analysis; protein levels were reduced to 16% after 48 h and 2% after 96 h in HTNC treated when compared with mock-treated cells. No protein was detectable 7 days after HTNC treatment confirming the complete deletion of Sfrs10 ( Fig. 5F and G).
We assessed the impact of Sfrs10 deletion on Smn and could not find any differences for FL-Smn transcript amounts in HTNC versus mock-treated cells (Fig. 5D ). The same was true for SMN protein level (Fig. 5F , H), which remained unchanged upon Sfrs10 deficiency in MEFs. Our results indicate that the splicing factor is dispensable in MEFs, at least for growth and also for correct FL-Smn splicing.
Sfrs10 deficiency in MEFs leads to a 3 -4-fold increase of a murine SmnD7 isoform
Mice carry only one copy of the Smn gene which corresponds to the human SMN1 and which has so far not been described to undergo alternative splicing (42, 43) . Owing to the high conservation of the ESE recognized by Sfrs10 in Smn exon 7, we hypothesized that deletion of Sfrs10 could also affect the correct Smn splicing and that a murine SmnD7 could be generated. However, primers designed to amplify both spliced forms (FL-Smn and SmnD7) failed to reveal any signal for SmnD7 (data not shown). We therefore designed primers spanning Smn exons 6/8 that specifically amplify only SmnD7 transcripts, which also differ in size from FL-Smn. Surprisingly, low levels of SmnD7 transcripts were detected in cDNAs derived from brain and spinal cord of wild-type animals (Supplementary Material, Fig. S2 ). SmnD7 transcripts were identified with three different primer sets ( Table 5 ), indicating that the Smn locus also generates low levels of SmnD7. The relative amount of SmnD7 increased 3 -4-fold upon HTNC-mediated Sfrs10 deletion as determined by qRT-PCR (Fig. 5E ). However, this has no significant impact on the overall FL-Smn levels. We therefore conclude that Sfrs10 has only a very weak impact on Smn splicing in fibroblast cells.
Mice deficient for Sfrs10 in motor neurons show no SMA-like phenotype Although Sfrs10 deletion in MEFs showed no effect on FL-Smn splicing, we could not rule out that motor neurons-the affected cell-type in SMA-behave differently than fibroblasts. To analyze a potential impact of Sfrs10 deletion on Smn in motor neurons, we generated a line deficient for Sfrs10 exclusively in motor neurons using the Hb9-Cre line (44) . Immunohistochemical analysis of spinal cord sec- ; Hb9-Cre mice. Concordantly, no noticeable deficits in motor abilities were observed in these mice even not at the age of 1 year. Mice were fertile and had normal lifespan. In contrast, SMA-like mice have been reported to develop a severe phenotype soon after birth (45, 46) . This in vivo data further strengthens the observation that Sfrs10 deficiency has no significant effect on Smn splicing in mice.
Sfrs10 deficiency has no effect on human SMN2 exon 7 splicing
Owing to the effect of Sfrs10 deficiency on murine Smn exon 7 splicing, we wondered whether it may have also an impact on the correct splicing of human SMN2. By in vitro experiments, SFRS10 has been shown to specifically bind exon 7 of SMN1 and SMN2, to facilitate exon 7 inclusion and to restore correct splicing (19, 20) . To investigate whether Sfrs10, which is 100% identical to SFRS10, has any effect on SMN2 splicing, we generated Smn Fig.7B and E) . Again the cells showed no proliferative deficits due to the Sfrs10 deficiency (Fig. 7A) . Surprisingly, any changes neither in FL-SMN2 nor in D7-SMN2 were not detectable at 48 h, 96 h, 7 days or 14 days after the HTNC-mediated deletion of the splicing factor as assessed by qRT-PCR (Fig. 7C, D and data not shown). Unexpectedly, on protein level even a 2.2-fold increase of SMN was observed upon the HTNC-mediated Sfrs10 deficiency 7 days after the treatment ( Fig.7E and F) . Owing to the fact that the Sfrs10 protein was completely depleted only at day 7 after HTNC treatment ( Fig. 5C ) and that the first impact on SMN was also visible at that time point, we additionally assessed day 14 post-treatment. Again an 1.9-fold upregulation of SMN was observed. This upregulation was not mediated by any HTNC-specific effect as HTNC-treated MEFs with the genotype Smn 2/2 ; SMN tg/tg ; Sfrs10 wt/wt generated within the same preparations as the floxed cells did not reveal any SMN upregulation (data not shown). Furthermore, we could not detect any upregulation of Sfrs10 complex partners such as SRp30c or TDP43 (data not shown). We also tested different antibodies for hnRNP-G, but none of them was able to detect this protein with the limited protein amounts which were available. Depletion of Sfrs10 may allow other splicing factors to bind SMN2 pre-mRNA and facilitate exon 7 inclusion. This hypothesis, however, is not supported by our findings of unmodified FL-SMN2 transcript levels. Further investigations are required and may answer this unexpected and controversial results.
Taken together, our data suggest that in vitro data reported for splicing factors may not be confirmed by in vivo data and that in vitro overexpression may create an artificial competition for the occupancy of splice sites.
DISCUSSION
SFRS10 is mainly involved in alternative splicing processes such as the inclusion of exon 7 into the SMN mRNA. Introduction of mutations in the ESE bound by SFRS10 results mainly in SMND7 transcripts. Increased levels of SFRS10 reverted the FL-SMN2 transcript levels from 10 to 80% (19, 20) . This is of particular interest in the context of a potential therapy in SMA patients based on reversion of SMN2 splicing towards higher levels of FL-SMN2 transcripts (47). The external 5 ′ probe (5 ′ P) was used for the detection of Sfrs10flneo ES cell clones, the for genotyping of Sfrs10flneo and Sfrs10floxed mice, the external 3 ′ probe (3 ′ P) was used for the detection of Sfrs10flneo ES cell clones, the internal neo probe (nP) was used to ensure single insertion of the Sfrs10 targeting construct in ES cell clones and the knockout probe (KOP) was used for genotyping of Sfrs10 knockout allele. 2158
Drugs like HDACi (e.g. valproic acid, M344, LBH589) increase not only FL-SMN levels but also SFRS10 (32, 34, 48) . However, a causal relationship between SFRS10 levels and increased splicing of SMN has not yet been established in vivo. Furthermore, it is crucial to identify the spectrum of transcripts, splicing of which is influenced by SFRS10, and thus to gain insight into potential long-term implications and side effects. To do so, we conditionally targeted the Sfrs10 gene in mice and generated Sfrs10 deficient animals via the Cre/loxP system. The ubiquitous deletion of the splicing factor resulted in early embryonic lethality around E7.5 and 8.5 indicating an essential role of Sfrs10 during embryonic development postimplantation. The Sfrs10 2/2 embryos detected at E8.5 and 9.5 showed severe growth retardation and no organogenesis. The only structure we identified in some of the Sfrs10 deficient embryos was the allantois, suggesting that the embryos seem to develop normally until E6.5. The observed phenotype implicates an essential role of the splicing factor in processes crucial for cell growth and differentiation. This suggestion was further supported by the finding that Sfrs10 is widely expressed as early as embryonic day E6.5. The process to form a multilayered embryo requires extensive proliferative capacity with an improved RNA metabolism (49) . The fact that Sfrs10 2/2 embryos stop development roughly at the stage of mid-gastrulation ( E6.5) suggests a critical role of Sfrs10 in those processes and a disturbance of general cellular processes due to the absence of Sfrs10.
Only few knockouts of splicing factors have been reported so far. The ablation of the SR splicing factor SRp20 has been shown to be lethal already immediately prior to blastocyst formation (50) . Similar results were found for SC35 and SF2/ASF knockouts (51, 52) , whereas the deletion of hnRNP-C (53) results in a similar phenotype as observed for Sfrs10 deficiency. However, Sfrs10 2/2 embryos seem to develop slightly beyond the stage in which hnRNP-C deficient embryos die. Interestingly, Sfrs10 does not seem to be necessary for cell viability per se, because HTNC-driven Sfrs10 deletion in MEFs did not result in cell death or reduced proliferation. The same is also true for cells deficient for hnRNP-C, which was shown to be dispensable for ES cell viability even though growth was slower when compared with wild-type cells (53) . In contrast, MEFs deficient for SF2/ ASF or SC35 underwent apoptosis early after ablation (54), demonstrating the essential role of these SR proteins for the splicing reaction per se. The early lethal phenotype reported here is opposed to that observed in Drosophila, in which ablation of Tra2 leads to transformation of genotypic females to phenotypic sterile males, but otherwise these flies develop normally. The Drosophila ortholog Tra2 acts in the cascade determining sexual differentiation (38) . Similarly, the mouse Sfrs10 seems to have an impact on spermatogenesis as it influences the splicing of testis-specific transcripts (13) . However, we could not observe any restrictions in fertility of Sfrs10 +/2 males even though reduced protein amounts ( 30%) were detected (Fig. 2B) . As the regulation of sexual differentiation is not conserved among Drosophila and mammals, the gain of new functions of Sfrs10 among evolution is perspicuous.
Initially, the definition of a splicing factor to be essential was derived from its ability to complement splicing deficient S100 extracts (1). As SFRS10 is dispensable for the splicing reaction as such, it is considered to be non-essential. Nevertheless, the tight control of alternatively spliced transcripts seems to be indispensable during embryogenesis as shown by the results reported here.
We further assessed the importance of Sfrs10 on Smn splicing by conducting the deletion of the splicing factor by HTNC in Sfrs10 fl/fl MEFs. It has previously been shown that the central part of Smn contains a strong AG-rich ESE similar to the one described in human SMN (19, 55, 56) . However, neither on protein nor on transcript levels any changes in FL-Smn concentrations were observed. Surprisingly, even though mice do not carry an SMN2 corresponding gene, SmnD7 was found to be expressed also in non-treated cells and in different tissues derived from wild-type animals. Previous studies did not detect the murine SmnD7 isoform most probably due to its very low level (55) . This isoform 
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was only detectable with SmnD7-specific primers, but not with primers that amplified both isoforms, pointing towards a high abundance of FL-Smn when compared with SmnD7. However, upon HTNC-mediated Sfrs10 deletion, the amount of SmnD7 increased up to 4-fold, suggesting that Sfrs10 has a minor role in murine Smn exon 7 inclusion. We therefore also investigated the role of Sfrs10 on SMN2 splicing, because the splicing factor has been reported to be the major actor on SMN2 exon 7 inclusion (19, 20) . The relevance of the central ESE to promote SMN2 exon 7 inclusion has further been demonstrated by the use of bifunctional SMN2 antisense oligos containing the SFRS10 binding region and an SR tail (57 -59 MEFs did not reveal any impact neither on FL-SMN2 nor on SMND7 splicing. These results do not entirely exclude the role of SFRS10 in SMN2 splicing. If enough SFRS10 is present it may still promote exon 7 inclusion. However, depletion of SFRS10 may allow other splicing factors to be recruited to SMN2 to substitute SFRS10 function and facilitate exon 7 inclusion. Future analyses are required to test this hypothesis and may allow to identify other splicing factors important for SMN2 splicing regulation. However, the practical limits of transfecting our HTNC-treated fibroblasts impeded any further analyses in that field. Furthermore, protein binding assays on in vitro transcribed RNA would also create an artificial situation barely reflecting native conditions. Furthermore, we generated a conditional Sfrs10 deficiency in motor neurons using the Hb9-Cre line (44) to verify whether Sfrs10 deletion has any effect on murine Smn splicing in vivo. If the sole Smn gene present in mice underwent aberrant splicing, the animals should develop an SMA-like phenotype as found in mice carrying the human SMN2 on Smn null background (45, 60) . However, despite the knockout of Sfrs10 in motor neurons-as shown by immunohistochemical stainings-the mice failed to show any phenotype even at the age of .1 year, further strengthening our observation that Sfrs10 has no significant effect on Smn splicing.
The generation of mice with other tissue-specific Sfrs10 deficiency (e.g. neuronal specific) will enable us to unravel the impact of Sfrs10 deficiency on SMN2 exon 7 splicing in vivo, but also on other already known or yet unknown alternatively spliced exons influenced by Sfrs10. Our current data suggest that deletion or overexpression of the same splicing factor is not automatically influencing alternatively spliced exons in an opposite fashion. The absence of a certain splicing factor, in our case a non-essential splicing factor, obviously allows another splicing factor(s) to occupy the specific RNA domain and to still regulate exon selection. Further alternatively spliced exons known to be regulated by Sfrs10 have to be analyzed in future in order to find out whether this unexpected result for SMN2 is unique or common for other transcripts. However, the early embryonic lethality caused by Sfrs10 depletion suggests that Sfrs10 is essential for the splice regulation of some transcripts and is not compensated-at least in that early developmental stage-by other splicing factors.
Taken together, our results demonstrate that Sfrs10 plays an important role during early embryonic development. Furthermore, we showed that Sfrs10 deficiency has no noteworthy effect on Smn and SMN2 splicing and that motor neuron-specific Sfrs10 deletion in mice has no phenotypic consequences, demonstrating its dispensability in certain cells or tissues. The Sfrs10 fl/fl mouse line will allow us to generate further tissue specific Sfrs10 deleted lines and to uncover the most important targets regulated by Sfrs10.
MATERIALS AND METHODS
Generation of conditional Sfrs10 mice
The targeting vector for Sfrs10 was generated by the use of the pRAPIDflirt vector (61) , which comprised an FRT-flanked PGKneoR cassette and the Herpes Simplex Virus thymidine kinase gene for positive and negative selection, respectively. * P, 0.05; * * P , 0.01; * * * P , 0.001.
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The 5 ′ and 3 ′ homology arms (3.1 and 5.2 kb, respectively) were amplified using the primers 5
′ and cloned into the BamHI and XhoI sites, respectively. The conditional region (621 bp) including exon 4 was amplified by primers 5 ′ GTCGACG TGACCACTTTATACAGAGGTAAAC3 ′ and 5 ′ GTCGACG TGACCACTTTATACAGAGGTAAAC3 ′ and was inserted by SalI between the two loxP sites. (Fig. 1A) . Fifty micrograms of NotI linearized targeting vector were electroporated into V6.5 (C57BL/6J × 129/Sv) F1 embryonic stem (ES) cells (62) . ES cell culture, transfection and selection of transfected clones were performed as previously described (63) . Of 400 clones surviving G418 and gancyclovir, four were found to be homologous recombinant by Southern blot analysis using all three hybridization probes.
Chimeric mice were generated by the injection of Sfrs10 flneo/+ ES cells into blastocysts of CB20 mice. Male chimeras were bred to C57BL6/N Crl females and germline transmission was confirmed by PCR (data not shown) and verified by Southern blot analysis (Fig. 1B) .
Mice heterozygous for Sfrs10 deficiency were obtained by mating Sfrs10 flneo/+ mice to the deleter-Cre line (40) and Sfrs10 +/2 offspring ( Fig. 1G and H) were intercrossed to obtain homozygous Sfrs10 2/2 mice. To generate Sfrs10 fl/+ mice, the FRT-flanked PGKneoR cassette was deleted in vivo by breeding Sfrs10 flneo/+ mice with FLPe-deleter mice (39) . Absence of the Neo(R) cassette was confirmed by PCR and Southern blot analysis (Fig. 1E and F) and respective animals (Sfrs10 fl/+ ) were bred to homozygosity.
To specifically delete Sfrs10 in motor neurons, Sfrs10 fl/fl mice were bred to Hb9-Cre transgenic mice (44) (kindly provided by S. Arber, Neurobiology Biozentrum, Basel). All Sfrs10 lines were backcrossed at least four generations to C57BL6/N Crl background. An overview of all generated Sfrs10 lines is given in Table 1 .
Animal care was performed according to the institutional animal care committee guidelines and German animal protection laws and were approved under the reference numbers 50.203.2-K 38, 19/05 and 9.93.2.10.31.07.292 of the 'Landesamt für Natur, Umwelt und Verbraucherschutz NRW'.
Genotype analysis
Genomic DNA was isolated from mouse tail tip biopsies, embryos or ES cells as previously described (64) . Homologous recombination events of Sfrs10 flneo/+ clones were identified by Southern blot analysis with 5 ′ and 3 ′ external genomic probes (5 ′ P and 3 ′ P) after restriction digest with PstI or NcoI, respectively (Fig. 1B and C) . To exclude additional random integrations of the Sfrs10 targeting construct an internal probe against the Neo(R) cassette was used after SacI restriction digest (Fig. 1D) . Primers used for the generation of probes are given in Table 2 .
Genotyping of mice and embryos was performed by PCR (Table 3 ). The genotype of each newly created Sfrs10 mouse line was confirmed by Southern blotting. DNA from blastocysts and embryos at E7.5 was amplified prior to PCR genotyping using the RepliG MINI Kit (Qiagen) according to the manufacturer's instructions. Genotyping of these embryos was confirmed by three independent PCR reactions using different primer combinations (Table 3 ). 
Preparation of embryos
Mice heterozygous for the Sfrs10 deficiency were mated to obtain Sfrs10 +/+ , Sfrs10 +/2 and Sfrs10 2/2 embryos. Vaginal plug inspection was used to assess the time point of pregnancies at E0.5. Females were sacrificed at the respective day of pregnancy and the uterine horns were dissected. To isolate E3.5 blastocysts, the uterine horns were flushed with M2 medium (65) , the isolated blastocysts were washed through three drops of fresh M2 medium and directly transferred into a PCR tube for amplification of genomic DNA and subsequent genotyping. Embryos of all other stages were dissected from deciduae and used for genotyping after lysis and subsequent DNA isolation.
Immunohistochemical analysis of embryos and spinal cord sections
Embryos were fixed in the deciduae in 4% PFA at 48C overnight, washed in PBS, dehydrated with increasing concentrations of ethanol, cleared in xylene and embedded in paraffin. Paraffin sections were serially produced at a thickness of 7 mm. Sections were deparaffined in xylol (twice for 1 h) and rehydrated (twice for 1 min 100% ethanol, 1 min 96% ethanol, 1 min 70% ethanol). For antigen retrieval, sections were boiled in citric acid buffer (0.01 M citric acid, pH 6) three times for 5 min each in a microwave and cooled to room temperature. Sections were washed in TBS (10 mM Tris-HCl, 0.15 M NaCl; pH 7.6) and unspecific binding was Primary MEFs were isolated from E13.5 embryos of Sfrs10 fl/fl or Smn 2/2 ; SMN2 tg/tg ; Sfrs10 fl/+ intercrosses. Embryos were dissected, head, heart and liver were removed and the remaining tissue was homogenized through a 70 mm cell strainer (BD Falcon) which was subsequently flushed with 10 ml DMEM medium (Invitrogen) supplemented with 10% FCS (Invitrogen), 100 U/ml penicillin (PAA), 100 mg/ ml streptomycin (PAA), 100 mM non-essential amino acids (PAA), 2 mM L-glutamine (PAA) and 1 mM sodium pyruvate (PAA). Cells were sedimented and resuspended in 5 ml medium before plated on gelatinized 6 cm tissue culture dishes (Sarsted). Cells were cultured at 378C, 5% CO 2 and 90% humidity. MEFs of the desired genotype Smn 2/2 ; SMN2 tg/tg ; Sfrs10 fl/fl were identified by genotyping the corresponding embryos.
Transduction of MEFs with Cre recombinase
Recombinant HTNC (41) 5 cells on one 6-well (Sarsted)] were incubated with HTNC or mock-treated (only DMEM/PBS). Cells were washed twice with PBS after 16 -18 h, supplemented with medium and harvested after 48, 96 h or 7 days, respectively. Cells analyzed after 14 days were splitted on day 7 from one 6-well to one 6 cm dish. The efficiency of the HTNC-driven recombination was assessed via PCR. Cells were counted in a Neubauer chamber. Each experiment was carried out three times.
RNA and protein extraction and analysis
Total RNA was isolated from MEFs using the RNAeasy mini kit (Qiagen) and QIAshredder according to the manufacturer's instructions. RNA concentration was determined using the RiboGreen RNA Quantification Kit (Invitrogen) and subsequent measurement on a TECAN Safire 2 . One hundred nanograms of RNA were reversed transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) and cDNA was subjected to an absolute qRT-PCR using LightCycler 1.5 (Roche) as previously described (33) . qRT-PCR was conducted two times for each RNA sample. PCR primers are listed in Table 5 . Analysis of the raw data of qRT-PCR was performed using the LightCycler Software Version 3.5.
For protein extraction, tissue samples were homogenized or MEFs were harvested by cell scrapping in RIPA lysis buffer (Sigma). Protein concentration was determined with standard Bradford protein assay and 6 -10 mg of total protein was resolved by 10% SDS-PAGE and transferred to nitrocellulose membrane (Schleicher and Schuell). Immunoblotting was performed with the following antibodies: rabbit anti-SFRS10 (1:2000) (20) , mouse anti-SMN (BD-Bioscience, 1:10,000), mouse anti-b-actin (Sigma, 1:20 000), horseradish peroxidase conjugated anti-rabbit IgG (Pierce, 1:20 000) and horseradish peroxidase conjugated goat anti-mouse IgG (Dianova, 1:10 000). Detection of the signals with the Chemiluminiscence reagent (Super Signal West Pico, Pierce) was carried out according to the manufacturer's protocol. Signal intensity was measured using the ONE-DScan program (Scanalytics). Protein data was normalized to the respective mock value and the internal control b-actin and given as mean + standard error of the mean.
Results were statistically interpreted by Microsoft Excel 2003 and Sigma Plot 9.0 (Systat Software, Inc.). To evaluate differences among data observed from mock or HTNC-treated cells, the Student's t-test was carried out. support, critical discussions and reagents. We thank Frank Edenhofer (Institute of Reconstructive Neurobiology, Bonn) for providing us with HTNC and Silvia Arber (Neurobiology Biozentrum, Basel) for the Hb9-Cre mice.
